SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer

NCT05093387 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped funding issues and pharmacy preparation for the drug

Conditions

Anatomic Stage IV Breast Cancer AJCC v8
Breast Inflammatory Carcinoma
Metastatic Triple-Negative Breast Carcinoma
Prognostic Stage IV Breast Cancer AJCC v8

Interventions

DRUG: Carboplatin
BIOLOGICAL: Pembrolizumab
GENETIC: Transferrin Receptor-Targeted Liposomal p53 cDNA

Sponsor

Northwestern University

Collaborators

[object Object]